223 related articles for article (PubMed ID: 34824158)
1. Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy.
Alvarez M; Molina C; De Andrea CE; Fernandez-Sendin M; Villalba M; Gonzalez-Gomariz J; Ochoa MC; Teijeira A; Glez-Vaz J; Aranda F; Sanmamed MF; Rodriguez-Ruiz ME; Fan X; Shen WH; Berraondo P; Quintero M; Melero I
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34824158
[TBL] [Abstract][Full Text] [Related]
2. Intratumoral BO-112 in combination with radiotherapy synergizes to achieve CD8 T-cell-mediated local tumor control.
Rodriguez-Ruiz ME; Serrano-Mendioroz I; Garate-Soraluze E; Sánchez-Mateos P; Barrio-Alonso C; Rodríguez López I; Diaz Pascual V; Arbea Moreno L; Alvarez M; Sanmamed MF; Perez-Gracia JL; Escuin-Ordinas H; Quintero M; Melero I
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36631161
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapeutic effects of intratumoral nanoplexed poly I:C.
Aznar MA; Planelles L; Perez-Olivares M; Molina C; Garasa S; Etxeberría I; Perez G; Rodriguez I; Bolaños E; Lopez-Casas P; Rodriguez-Ruiz ME; Perez-Gracia JL; Marquez-Rodas I; Teijeira A; Quintero M; Melero I
J Immunother Cancer; 2019 May; 7(1):116. PubMed ID: 31046839
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of LCMV-based cancer immunotherapies is unleashed by intratumoral injections of polyI:C.
Gomar C; Di Trani CA; Bella A; Arrizabalaga L; Gonzalez-Gomariz J; Fernandez-Sendin M; Alvarez M; Russo-Cabrera JS; Ardaiz N; Aranda F; Schippers T; Quintero M; Melero I; Orlinger KK; Lauterbach H; Berraondo P
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38631714
[TBL] [Abstract][Full Text] [Related]
5. Intratumoral injection of interferon-α and systemic delivery of agonist anti-CD137 monoclonal antibodies synergize for immunotherapy.
Dubrot J; Palazón A; Alfaro C; Azpilikueta A; Ochoa MC; Rouzaut A; Martinez-Forero I; Teijeira A; Berraondo P; Le Bon A; Hervás-Stubbs S; Melero I
Int J Cancer; 2011 Jan; 128(1):105-18. PubMed ID: 20309938
[TBL] [Abstract][Full Text] [Related]
6. Intratumoral Immunotherapy with XCL1 and sFlt3L Encoded in Recombinant Semliki Forest Virus-Derived Vectors Fosters Dendritic Cell-Mediated T-cell Cross-Priming.
Sánchez-Paulete AR; Teijeira Á; Quetglas JI; Rodríguez-Ruiz ME; Sánchez-Arráez Á; Labiano S; Etxeberria I; Azpilikueta A; Bolaños E; Ballesteros-Briones MC; Casares N; Quezada SA; Berraondo P; Sancho D; Smerdou C; Melero I
Cancer Res; 2018 Dec; 78(23):6643-6654. PubMed ID: 30297531
[TBL] [Abstract][Full Text] [Related]
7. Intratumoral neoadjuvant immunotherapy based on the BO-112 viral RNA mimetic.
Alvarez M; Molina C; Garasa S; Ochoa MC; Rodriguez-Ruiz ME; Gomis G; Cirella A; Olivera I; Glez-Vaz J; Gonzalez-Gomariz J; Luri-Rey C; Azpilikueta A; Bolaños E; Teijeira A; Berraondo P; Quintero M; Melero I
Oncoimmunology; 2023; 12(1):2197370. PubMed ID: 37035637
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral injection of interferon-gamma gene-modified dendritic cells elicits potent antitumor effects: effective induction of tumor-specific CD8+ CTL response.
Pan J; Zhang M; Wang J; Wang Q; Xia D; Sun W; Zhang L; Yu H; Cao X
J Cancer Res Clin Oncol; 2005 Jul; 131(7):468-78. PubMed ID: 15711825
[TBL] [Abstract][Full Text] [Related]
9. STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity.
Demaria O; De Gassart A; Coso S; Gestermann N; Di Domizio J; Flatz L; Gaide O; Michielin O; Hwu P; Petrova TV; Martinon F; Modlin RL; Speiser DE; Gilliet M
Proc Natl Acad Sci U S A; 2015 Dec; 112(50):15408-13. PubMed ID: 26607445
[TBL] [Abstract][Full Text] [Related]
10. STING Activated Tumor-Intrinsic Type I Interferon Signaling Promotes CXCR3 Dependent Antitumor Immunity in Pancreatic Cancer.
Vonderhaar EP; Barnekow NS; McAllister D; McOlash L; Eid MA; Riese MJ; Tarakanova VL; Johnson BD; Dwinell MB
Cell Mol Gastroenterol Hepatol; 2021; 12(1):41-58. PubMed ID: 33548597
[TBL] [Abstract][Full Text] [Related]
11. Enhancing immunotherapy of STING agonist for lymphoma in preclinical models.
Sallets A; Robinson S; Kardosh A; Levy R
Blood Adv; 2018 Sep; 2(17):2230-2241. PubMed ID: 30194137
[TBL] [Abstract][Full Text] [Related]
12. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW
Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751
[TBL] [Abstract][Full Text] [Related]
13. Influence of injection technique, drug formulation and tumor microenvironment on intratumoral immunotherapy delivery and efficacy.
Muñoz NM; Williams M; Dixon K; Dupuis C; McWatters A; Avritscher R; Manrique SZ; McHugh K; Murthy R; Tam A; Naing A; Patel SP; Leach D; Hartgerink JD; Young S; Prakash P; Hwu P; Sheth RA
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589526
[TBL] [Abstract][Full Text] [Related]
14. Epitope spreading driven by the joint action of CART cells and pharmacological STING stimulation counteracts tumor escape via antigen-loss variants.
Conde E; Vercher E; Soria-Castellano M; Suarez-Olmos J; Mancheño U; Elizalde E; Rodriguez ML; Glez-Vaz J; Casares N; Rodríguez-García E; Hommel M; González-Aseguinolaza G; Uranga-Murillo I; Pardo J; Alkorta G; Melero I; Lasarte J; Hervas-Stubbs S
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34810235
[TBL] [Abstract][Full Text] [Related]
15. Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy.
Wang D; Jiang W; Zhu F; Mao X; Agrawal S
Int J Oncol; 2018 Sep; 53(3):1193-1203. PubMed ID: 29956749
[TBL] [Abstract][Full Text] [Related]
16. Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma.
Jassar AS; Suzuki E; Kapoor V; Sun J; Silverberg MB; Cheung L; Burdick MD; Strieter RM; Ching LM; Kaiser LR; Albelda SM
Cancer Res; 2005 Dec; 65(24):11752-61. PubMed ID: 16357188
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+ T cells.
Wang S; Campos J; Gallotta M; Gong M; Crain C; Naik E; Coffman RL; Guiducci C
Proc Natl Acad Sci U S A; 2016 Nov; 113(46):E7240-E7249. PubMed ID: 27799536
[TBL] [Abstract][Full Text] [Related]
18. Poly-IC enhances the effectiveness of cancer immunotherapy by promoting T cell tumor infiltration.
Sultan H; Wu J; Fesenkova VI; Fan AE; Addis D; Salazar AM; Celis E
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32958686
[TBL] [Abstract][Full Text] [Related]
19. Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumors.
Márquez-Rodas I; Longo F; Rodriguez-Ruiz ME; Calles A; Ponce S; Jove M; Rubio-Viqueira B; Perez-Gracia JL; Gómez-Rueda A; López-Tarruella S; Ponz-Sarvise M; Álvarez R; Soria-Rivas A; de Miguel E; Ramos-Medina R; Castañon E; Gajate P; Sempere-Ortega C; Jiménez-Aguilar E; Aznar MA; Calvo A; Lopez-Casas PP; Martín-Algarra S; Martín M; Tersago D; Quintero M; Melero I
Sci Transl Med; 2020 Oct; 12(565):. PubMed ID: 33055241
[TBL] [Abstract][Full Text] [Related]
20. Regression of established AB1 murine mesothelioma induced by peritumoral injections of CpG oligodeoxynucleotide either alone or in combination with poly(I:C) and CD40 ligand plasmid DNA.
Stone GW; Barzee S; Snarsky V; Santucci C; Tran B; Kornbluth RS
J Thorac Oncol; 2009 Jul; 4(7):802-8. PubMed ID: 19550243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
